Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Controversies in upper GI oncology: ESMO Open Podcasts

The selection of Standard of Care is still one of the hottest controversial topics in upper gastrointestinal tumours. In this ESMO Podcast series, experts debate about the pros and cons of each approach alongside with future perspectives, biomarkers and implication for patients’ selection.


Controversies in upper GI oncology: Early-onset Gastric Cancer

In this podcast, Dr Angelica Petrillo, gastrointestinal oncologist of Ospedale del Mare, Naples, Italy, presents a debate between Prof Irit Ben-Aharon, medical oncologist of Fishman Oncology Center, Haifa, Israel, and Dr Maria Alsina, medical oncologist of Hospital Universitario de Navarra, Pamplona, Spain, regarding early-onset gastric cancer.

Published in February 2024


Controversies in upper GI oncology: MSI-H in Gastric Cancer

In this podcast, Dr Elizabeth Smyth, of Oxford University Hospitals, Oxford, UK, and Dr Sarah Derks, of Amsterdam UMC, Amsterdam, the Netherlands discuss developments in research on high-frequency microsatellite instability (MSI-H) in gastric cancer, with ESMO Faculty member Dr Angelica Petrillo of Ospedale del Mare, Naples, Italy.

Published in December 2023


Controversies in upper GI oncology: Liquid Biopsy

One of controversial topics in modern upper GI oncology is the use of liquid biopsies as a decision tool for personalised treatments. Today we are addressing this topic bringing on board the experience and point of view of two international experts in the field: Dr Filippo Pietrantonio, a clinician, and Dr Dominic Rothwell, a scientist.

Published in October 2023


Controversies in upper GI oncology: 1st line systemic treatment in MASLD-associated HCC

Dr Matthias Pinter, of the Medical University of Vienna, Austria, and Andrea Casadei Gardini, of University Vita-Salute San Raffaele, Milan, Italy, discuss with Dr Jeroen Dekervel, of UZ Leuven, Belgium, the merits of immunotherapy vs TKI in the first-line systemic treatment of MASLD-associated HCC.

Published in September 2023


Controversies in upper GI oncology: Maintenance treatment in pancreatic cancer

Dr Jeroen Dekervel, GI Oncologist, UZ Leuven, Belgium, presents a debate between Dr Eileen O’Reilly, Medical Oncologist, MSKCC, New York, and Dr Daniel Laheru, Medical Oncologist, Johns Hopkins, Baltimore, Maryland considering maintenance treatment in pancreatic cancer.

Published in April 2023


Controversies in upper GI oncology: First-line checkpoint inhibitor use in metastatic GEA

In this podcast, Dr. Angelica Petrillo interviews Dr. Steven Maron and Dr. Raghav Sundar about the following issue: First-line checkpoint inhibitor use in metastatic gastroesophageal adenocarcinoma (GEA): guided by PD-L1 combined positive score (CPS) or not? The two experts debate about the pros and cons of using PD-L1 CPS to select patients as well as future perspectives.

Published in March 2023


Controversies in upper GI oncology: Neoadjuvant CRT vs neoadjuvant CT in oesophageal adenocarcinoma

In this podcast, Dr Angelica Petrillo interviews Prof Hanneke WM van Laarhoven and Prof Sylvie Lorenzen about the best choice for neoadjuvant treatment for non-metastatic oesophageal adenocarcinoma: chemoradiotherapy or chemotherapy? The two experts debate about the pros and cons of each approach alongside with future perspectives, biomarkers and implication for patients’ selection.

Published in September 2022

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.